GSK3 BETA-INHIBITORY ACTIVITY IN MICROFUNGAL ISOLATED FROM SABAH RAINFOREST SOILS



FACULTY OF SCIENCE AND NATURAL RESOURCES UNIVERSITI MALAYSIA SABAH 2017

GSK3 BETA-INHIBITORY ACTIVITY IN MICROFUNGAL ISOLATED FROM SABAH RAINFOREST SOILS

DG. NUR AZIERAH FACHYUNI ABDUL AZIZ



FACULTY OF SCIENCE AND NATURAL RESOURCES UNIVERSITI MALAYSIA SABAH 2017

DECLARATION

I hereby declare that the material in this thesis is my own except for quotations, excerpts, equations, summaries, and references which have been duly acknowledged.

29 February 2016

Dg. Nur Azierah Fachyuni Abdul Aziz PS 20118157



CERTIFICATION

NAME	:	DG. NUR AZIERAH FACHYUNI ABDUL AZIZ
MATRIC NO.	:	PS20118157
TITLE	:	GSK3 BETA-INHIBITORY ACTIVITY IN
		MICROFUNGAL ISOLATED FROM SABAH
		RAINFOREST SOILS
DEGREE	:	MASTER OF SCIENCE (BIOTECHNOLOGY)
VIVA DATE	:	20 JANUARY 2017





2. CO-SUPERVISOR

Assoc. Prof. Dr. How Siew Eng

Signature

ACKNOWLEDGEMENT

Alhamdulillah to Almighty Allah s.w.t. for giving me strength and patience to complete this research works. My great appreciation goes to my main supervisor Associate Professor Dr. Lee Ping Chin. Her guidance in scientific knowledges, motivations and warm kindness has made my research become meaningful. Great thanks also to my co-supervisor Associate Professor Dr. How Siew Eng that encourage me to learn more about organic chemistry which ultimately improved my chemistry knowledge. Thank you also to Associate Professor Dr. Jualang Azlan Gansau, Associate Professor Dr. Zaleha Aziz and Miss Hartinie Marbawi for giving me valuable motivation and spirits. Thanks to Dr. Ling Yee Soon and Yoong Soon Yong for their guidance, assistance and warm kindness which I will never forget. Sincere thanks to MOSTI for the grant and scholarship scheme.

I dedicated this study to my parents Haji Abdul Aziz Ahmad and Samarah@Hasrah Nurajim which never give up on me, understand my works and very supportive in every matters. Thank you and I love you so much. My warm gratitude also goes to my siblings, cousins and close relative for their motivations, spirits and financial supports. Endless thankful goes to Aidy Michael for his strength and patience on me in every best and worst situation throughout the years.

UNIVERSITI MALAYSIA SABAH

My gratefulness also goes to my seniors and close friend in the laboratory; Fauze Mahmud, Norhanizah Johansah, Aizuddin Abdullah, Eric Tzyy Jiann Chong, Lucky Poh Wah Goh, Nur Ashikin Gandah, Cherry Prissie Philip Jukim, Pan Shing Yi, Leong Yeh Chwan and Sakinah Yusof. Thank you so much for every act of kindness, inspiration and motivation during my study. Not to forget to thank the kindness from Puan Nadirah Yusof, Encik Asram Rasmun and Puan Nur Hidayah Thaddeus Abdullah for the chemical/reagents, instruments and laboratory that I used during my master study.

Dg. Nur Azierah Fachyuni Abdul Aziz 29 February 2016

ABSTRACT

Glycogen synthase kinase-3 β (GSK-3 β) is a serine/threonine kinase that has been implicated in several diseases such as diabetes, cancer, inflammation, Alzheimer and bipolar disorder. Therefore, GSK-3 β has become a prior target in drug discovery. This study was aimed to search for potential GSK-3ß inhibitors in soil microfungi isolated from Sabah rainforests. In this study, a total of 122 soil samples were collected from west coast and interior division of Sabah whereby 165 microfungi strains were successfully isolated on potato dextrose agar and malt extract agar. All strain was cultured aerobically and the prepared extracts were tested using a yeast-based screening assay for their inhibitory activity on GSK-38. The homologous genes of GSK-3 in the yeast (MCK1, MDS1, MRK1, and YOL128C) were knocked out and inserted with mammalian GSK-3ß to overcome temperaturesensitive phenotype of the mutant at 37°C thus created a yeast strain that is capable to grow at both 25°C and 37°C. Positive result was scored when there is a large inhibition zone on the grown yeast at 37°C. Furthermore, targeting Cys199 residue on GSK-3ß is a possible mechanism of inhibition in this assay and this residue lead to a selective inhibitor. Fourteen out of 165 strains gave detectable inhibition zones in the screening assay but only one strain namely MAN15558 isolated from Mantanani's island gave consistent inhibitory activities at 37°C and 25°C which were 17.75 mm \pm 0.35 (clear inhibition) and 11.5 mm \pm 0.53 (partial inhibition), respectively when tested at 5 mg/disk of acetone crude extracts. The MAN15558 strain is classified as *Aspergillus* sp. based on morphology and molecular techniques using 18sRNA. This strain is also a non-virulence strain based on biochemical assay. Crude extracts of MAN15558 strain was separated into polar and non-polar layer using rapid extraction method. Non-polar layer showed potential inhibitory activity at 100 µg/disk thus further fractionation of this layer was performed using automated semi preparative HPLC. Impure fraction 2 (F2) was obtained and the inhibitory activity on GSK-3 β was confirmed using screening assay (100 μ g/disk) and Kinase-Glo luminescent assay (10 μ g). Active F2 was analysed using LC-MS/Qtof and 639.1664 m/z detected as the potential precursor ion. Identification of compounds performed using MS/MS fragmentation data of 639.1664 m/z in MassBank programme. Five hits were obtained and two of it was predicted as the potential compound based on their chemical substructure and peak relationship. The compounds were Isoscoparin 2"-O-ferulate and Okanin 4'-(4"-acetyl-6"-p-coumarylglucoside). These compounds were predicted as anti GSK-3β agent produced by MAN15558 strain. They are flavonoid compound and contain sub-structure like ferulic acid and coumaric acid which confers anti-diabetic and anti-oxidant activity as reported extensively. Further purification and structure are required to confirm these compounds. This present study concluded that MAN15558 strain is the first soil microfungi isolated from Mantanani's island

identified as *Aspergillus* sp. that has produced anti GSK-3 β agents targeting on Cys199 and predicted as Isoscoparin 2"-O-ferulate and Okanin 4'-(4"-acetyl-6"-p-coumarylglucoside).



ABSTRAK

GSK3 BETA-INHIBITORY ACTIVITY IN MICROFUNGAL ISOLATED FROM SABAH RAINFOREST SOILS

Glikogen sintase kinase-3\beta (GSK-3\beta) adalah serin/threonin kinase yang terlibat dalam pelbagai penyakit seperti diabetes, kanser, inflamasi, Alzheimer dan gangguan bipolar. Maka, GSK-3ß telah menjadi sasaran utama dalam pencarian ubat-ubatan. Kajian ini mensasarkan pencarian perencat GSK-3β dalam mikrofungi tanah yang dipencilkan dari hutan hujan di Sabah. Dalam kajian ini, sebanyak 122 sampel tanah dikumpulkan dari pantai barat dan kawasan pedalaman Sabah yang mana 165 strain mikrofungi telah dipencilkan di atas agar dektros kentang dan agar ekstrak gandum. Semua strain dikulturkan secara aerobik dan ekstrak yang disediakan diuji dengan kaedah penyaringan menggunakan yis untuk penyaringan aktiviti perencatan ke atas GSK-3B. Gen homolog GSK-3 di dalam yis (MCK1, MDS1, MRK1, dan YOL128C) dikeluarkan dan digantikan dengan GSK-3β mamalia untuk mengatasi fenotip mutan yang sensitif-suhu pada 3PC seterusnya mencipta strain yis yang dapat tumbuh pada 25°C dan 37°C. Keputusan yang positif akan diskorkan apabila terdapat perencatan yang besar pada pertumbuhan yis di suhu 37°C. Selain itu, pensasaran Cys199 di GSK-3β merupakan mekanisma perencatan yang berkemungkinan untuk kaedah ini dan sasaran ini akan membawa kepada perencat yang selektif. Empat belas daripada 165 strain yang diuji menunjukkan kehadiran zon perencatan dalam kaedah penyaringan tetapi hanya satu strain dengan nama MAN15558 yang dipencilkan dari Pulau Mantanani memberikan aktiviti perencatan yang konsisten pada suhu 3PC dan $25^{\circ}C$ iaitu 17.75 mm ± 0.35 (perencatan jelas) dan 11.5 mm ± 0.53 (perencatan separa) masing-masing pada 5 mg/disk aseton ekstrak yg diuji. Strain MAN15558 diklasifikasikan sebagai Aspergillus sp. berdasarkan morfologi dan teknik molekular menggunakan 18sRNA. Strain ini juga tidak virulen berdasarkan ujian biokimia. Ekstrak daripada strain MAN15558 dipisahkan kepada bahagian polar dan tidak polar menggunakan kaedah ekstraksi cepat. Bahagian tidak polar menunjukkan aktiviti perencatan yang berpotensi pada 100 µg/disk seterusnya bahagian ini menjalani pemeringkatan lanjutan menggunakan semi preparative HPLC yang automatik. Pecahan aktif separa asli 2 (F2) telah diperoleh dan aktiviti perencatannya ke atas GSK-3β disahkan menggunakan kaedah penyaringn (100 µg/disk) dan kaedah luminesen Kinase-Glo (10 µg). Aktif F2 dianalisis menggunakan LC-MS/Qtof dan 639.1664 m/z dikesan sebagai ion prekursor yang berpotensi. Pengenalpastian sebatian dilaksanakan menggunakan data fragmentasi MS/MS 639.1664 m/z dalam program MassBank. Lima hit diperoleh dan dua daripadanya diramalkan sebagai sebatian yang berpotensi berdasarkan hubungan sub-struktur kimia dan fragmen. Sebatian itu adalah Isoscoparin 2"-O-ferulate dan Okanin 4'-(4"-acetyl-6"-p-coumarylqlucoside). Sebatian ini diramalkan sebagai agen anti GSK-3β dihasilkan oleh MAN15558 strain.

Sebatian ini merupakan sebatian flavonoid dan mempunyai sub-struktur seperti asid ferulik dan asid komarin yang memberikan anti-diabetik dan anti-oksidan aktiviti seperti yang dilaporkan secara meluas. Purifikasi dan struktur lanjutan adalah diperlukan untuk mengesahkan sebatian-sebatian ini. Kajian ini menyimpulkan bahawa strain MAN15558 merupakan mikrofungi tanah yang pertama dipencilkan dari Pulau Mantanani dikenalpasti sebagai Aspergillus sp. yang menghasilkan agen anti GSK-3 β yang mensasarkan Cys199 dan diramalkan sebagai Isoscoparin 2"-O-ferulate dan Okanin 4'-(4"-acetyl-6"-p-coumarylglucoside).



TABLE OF CONTENTS

			Page
TITLE	E		i
DECL	ARATIO	DN	ii
CERT	IFICAT	ION	iii
ACKN	IOWLED	GEMENT	iv
ABST	RACT		v
ABST	RAK		vii
TABL	e of co	INTENTS	ix
LIST	OF TAB	LES	xiii
LIST	OF FIGl	JRES	xv
LIST	OF PHO	TOS	xvii
LIST	OF ABB	REVIATIONS	xviii
LIST OF SYMBOLS			XX
LIST	OF APP	ENDICES	xxi
СНАР	TER 1:	INTRODUCTION	1
СНАР	TER 2:	LITERATURE REVIEW SITI MALAYSIA SABAH	4
2.1	Glycoge	en Synthase Kinase-3 (GSK-3)	4
	2.1.1	Substrate of GSK-3	6
	2.1.2	Regulation of GSK-3	9
	2.1.3	Important residue on GSK-3	10
2.2	Disease	es related to GSK-3 regulation	15
	2.2.1	Diabetes and insulin resistance (glycogen metabolism)	15
	2.2.2	Central nervous system disorders (Tau hyperphosphorylation)	16
	2.2.3	Cardiac myocyte hypertrophy (Wnt signaling)	17
	2.2.4	Cancer (cell fates)	18
2.3	Source	s of GSK-3 inhibitor compounds	19
2.4	Mechar	nisms and inhibition mode for GSK-3 inhibitor	24
	2.4.1	Lithium	24

	2.4.2	Indirubin-3'-monoxime	25
	2.4.3	Staurosporine	26
	2.4.4	TDZD-8	27
2.5	Second	lary metabolites and extraction techniques	29
2.6	Microfu	Ingi-Overview and classification	31
2.7	Soils m	icrofungi from tropical region	36
2.8	Involve	ement of microfungi metabolites with GSK-3β	38
2.9	Assays	for GSK-3 inhibitor	43
	2.9.1	<i>In vitro</i> assay	43
	2.9.2	In vivo and cell-based assay	44
СНА	PTER 3:	MATERIALS AND METHODS	46
3.1	Positive	e microfungi strain from stock	46
	3.1.1	Media preparation for microfungi strain	46
	3.1.2	Extraction of secondary metabolites from potential microfungi	47
	(Y	strain	
3.2	A yeas	st cell-based screening system targeting glycogen synthase	48
Z	kinase-	зв	
8	3.2.1	Genetic overview of transformed yeast	48
	3.2.2	Material preparation for screening assay	48
	3.2.3	Screening Assay	49
	3.2.4	Expected results from screening assay	50
3.3	Charac	terization and identification of MAN15558 strain	51
	3.3.1	Microscopic studies	51
	3.3.2	Molecular studies	52
	3.3.3	Biochemical studies	55
3.4	Charact	erization of secondary metabolites from shaked-flask culture of	56
	MAN15	558 strain	
	3.4.1	Cultivation media	56
	3.4.2	Effect of acetone treatment	57
	3.4.3	Growth curve of MAN15558 strain	57
3.5	Fraction	nations of crude extract from MAN15558 strain	57

	3.5.1	Overview of crude extracts preparation	57
	3.5.2	First fractionation approach	58
	3.5.3	Second fractionation approach	63
3.6	Kinase-	Glo luminescent assay	64
CHAI	PTER 4:	RESULT	66
4.1	Microfu	ngi strains	66
4.2	Microfu	ngi strains from stock	66
4.3	Strain c	onfirmation for inhibitory activity on GSK-3β in screening assay	67
4.4	Charac	terization of MAN15558 strain	68
	4.4.1	Morphology structure	68
	4.4.2	Molecular analysis	72
	4.4.3	Biochemical analysis	74
4.5	Optimiz	ation of secondary metabolites production for MAN15558 strain	76
	4.5.1	Cultivation media and acetone effects	76
	4.5.2	Growth curve based on biomass and inhibitory activity	78
4.6	Analysi	s for fractions from MAN15558 strain	80
2	4 <mark>.6.1</mark>	Analysis from first fractionation approach	80
R	4.6.2	Analysis from second fractionation approach	87
	4.6.3	Comparison between first and second fractionation approach	93
4.7	Anti GS	K-3β activity in Kinase-Glo luminescent assay	95
CHAI	PTER 5:	DISCUSSION	96
5.1	Isolatic	n and purification of microfungi strains	96
5.2	Screen	ing for anti-GSK-3β agent from microfungi extract	98
5.3	Identifi	cation and characterization of MAN15558 strain	100
5.4	Optimiz	ation of secondary metabolites production and growth curve	103
	for MAI	N15558 strain	
5.5	Analysi	s for active fraction and compound prediction for MAN15558	105
	strain		
5.6	Confirn	nation of GSK-3 β inhibition using enzymatic assay	113

	CHAP	TER 6: CONCLUSION	115
	6.1	Summarization of study	115
	6.2	Conclusion of study	116
REFERENCES		117	
APPENDIX 141		141	



LIST OF TABLES

	F	Page
Table 2.1:	List of several GSK-3 substrates ranging from transcription factors, structural proteins and metabolic proteins, their priming kinase and effects of GSK-3 phosphorylation	8
Table 2.2:	Amino acids residues and their location on GSK-3 β	11
Table 2.3:	Anti GSK-3 compounds classified under different sources	23
Table 2.4:	Type of GSK-3 inhibitor and their concentration used in vitro assay and in cell assay	29
Table 2.5:	Differences between chytridiomycota, zygomycota, glomeromycota, ascomycota and basidiomycota	33
Table 2.6:	Protein kinase inhibitor from microfungi metabolites and their reported IC ₅₀ value	40
Table 3.1:	Components of a master mix for PCR	53
Table 3.2:	Amplification condition for PCR process SIA SABAH	54
Table 3.3:	Solvents and mixed solvents used for developing TLC plate	59
Table 3.4:	Description of gradient solvent system used in column chromatography	60
Table 3.5:	Gradient method for fractions profiling and collecting sub-fraction using RP-HPLC	61
Table 3.6:	Setting parameter for dual ESI in QTOF	62
Table 3.7:	Semi preparative HPLC method for fraction collection	64
Table 4.1:	Inhibitory activity of four strains from different time of screening assay	68

Table 4.2:	Several hits from BLASTn aligned with the query sequence of MAN15558 strain	74
Table 4.3:	Carbon and chemical consumption by MAN15558 strain	75
Table 4.4:	Details of morphology and inhibitory activity for MAN15558 strain	77
Table 4.5:	Inhibitory activity of each partition from LLE on GSK- 3β	80
Table 4.6:	Inhibitory activity of fractions collected from column chromatography	82
Table 4.7:	Retention time, physical appearance and inhibitory activity for sub-fractions collected using RP-HPLC from F27	85
Table 4.8:	Compounds detected by GC-MS from sub fraction 27-3 and their inhibitory activity in screening assay	87
Table 4.9:	Inhibitory activity for fractions from non-polar layer of MAN15558 strain collected using semi preparative HPLC	90
Table 4.10:	Compounds hit from MassBank for precursor ion 639.1664 m/z	92
Table 4.11:	Summarization of comparisons between the first and second fractionation approach	94

LIST OF FIGURES

		raye
Figure 2.1:	GSK-3 β structures. Yellow is N-terminal domain, magenta is a-helical domain and blue is C-terminal domain. N-terminal consists of the first 134 residues that form a 7-strand β -barrel. A short linker (residues 135-151) from N-terminal connects N- terminal to a-helical domain (residues 152-342). Sandwiched between the N-terminal and a-helical domain is an ATP-binding site. The C-terminal consists of residues 343-433	5
Figure 2.2:	Schematic diagram of GSK-3 roles in glycogen and protein synthesis	17
Figure 2.3:	Indonesian sponge, <i>Acanthostrongylophora ingens</i> with the image of a colony of <i>Micromonospora</i> sp. strain M42, orange mycelial growth and black spores (left) which produced compound of Manzamine A (right)	21
Figure 2.4:	Some of commercialized GSK-3 inhibitors	24
Figure 2.5:	The effects of TDZD-8 experimented on adult mice brains generated with tumors GL261 glioma cells presents high reducing of growth tumor	28
Figure 2.6:	Scanning electron micrograph of <i>Tolypocladium inflatum</i> , ascomycete fungus (left) and its compound- cyclosporine (right)	35
Figure 2.7:	Aerial view of <i>Aspergillus terreus</i> (left) and its compound-lovastatin (right)	35
Figure 2.8:	From left: aerial view of <i>Penicillium</i> sp. on czapek yeast extract agar (1) and malt extract agar (2). In the middle: substrate view of <i>Penicillium</i> sp. czapek yeast extract agar (3) and malt extract agar (4). On the right: <i>Penicillium</i> sp. conidiophores under magnification 1 KX. Bar= 10 μ m	38

xv

Figure 2.9:	Single colony of <i>Penicillium</i> sp. strain KF620 overlapped with eutypoid C compound (left) and others eutypoid compounds B-E (right)	39
Figure 2.10:	<i>Aspergillus</i> sp. LF660 produced GSK-3β inhibitors namely pannorin. Aerial mycelium side (left) and Substrate mycelium side (middle) and pannorin structure (right)	42
Figure 2.11:	<i>Botryotinia fuckeliana</i> KF666 produced GSK-3β inhibitors namely alternariol (2) and alternariol-9-methylether (3)	43
Figure 3.1:	Map of Sabah	47
Figure 3.2:	Expected result in the screening assay	50
Figure 4.1:	DNA of MAN15558 after PCR using universal primer ITS1 and ITS4 with size approximately 550 bp using 1 % (w/v) of gel electrophoresis	73
Figure 4.2:	Growth curve for cultures of MAN15558 strain. 0 to 48 hours is the lag phase, 48 to 72 hours is the log phase, 72 to 96 hours is the stationary phase and 96 hours onwards is the death phase	79
Figure 4.3:	Graph of inhibition zone against time. Red line represents the inhibition zones measured at 37° C while blue line represents the inhibition zones measured at 25°C. Detectable inhibition zone was highest at 72 hours with 15.5 mm ± 0.71 at 37° C and only 10.3 mm ± 2.47 at 25° C	79
Figure 4.4:	RP-HPLC profile for fraction 27 whereas sub-fraction 27-3 was collected from retention time 10.26 minute to 10.83 minute (in circle)	84
Figure 4.5:	GC-MS profile for sub-fraction 27-3	86
Figure 4.6:	HPLC chromatogram (above) and contour plot (below) for non-polar layer from crude extracts of MAN15558 strain	89
Figure 4.7:	Graph of relative luminescence units (RLU) versus ATP concentration (0.06, 0.1, 0.3, 1, 3 and 6 μ M) for blank reaction, normal reaction and inhibitor reaction (fraction 2)	95

LIST OF PHOTOS

		Page
Photo 4.1a:	Spot culture of microfungi strain-MAN15558 purified on MEA	68
Photo 4.1b:	Inhibition zone by crude extracts of MAN15558 at 5 mg/disk in the screening assay (inhibition zone = $37^{\circ}C$: 17.75 mm ± 0.35; 25°C: 11.5 mm ±3.53, partial)	68
Photo 4.2:	MAN15558 strain on the agar observed with light microscope using 5X (left photo) and 10X (right photo) magnifications	69
Photo 4.3:	(a) A single conidiophore and some of conidia detached from the conidial head of MAN15558 observed under 40X of light microscope. (b) Zoom in of conidial head stained with lacto-phenol blue solution observed under 100X of light microscope	70
Photo 4.4:	Surface of a single conidiophore of MAN15558 strain using scanning electron microscope (SEM)	70
Photo 4.5:	Conidiophore of MAN15558 strain and a chain of conidia or conidiospores were observed to be attached to the conidial head	71
Photo 4.6:	Close up of a conidiophore have exposed the external features of the conidia (spores). The spores exhibited a circular, oval and concave shape while the surfaces of spores were covered with spikes	71
Photo 4.7:	MAN15558 strain on PDA after 8 days incubation at 28°C	77
Photo 4.8:	MAN15558 strain on MEA after 6 days incubation at 28°C	77
Photo 4.9:	Developed TLC and screening plate for F27. A clear inhibition zone (9 mm ± 0.15) at 37°C while no detectable inhibition zone at 25°C observed for 80 μ g/disk tested in the screening assay	83

LIST OF ABBREVIATIONS

АТР	- Adenosine triphosphate
Arg	- Arginine
Asn	- Asparagine
Asp	- Aspartic acid
C18	- Carbon 18
C-terminal	- Carboxyl-terminal
CDK	- Cyclin dependent kinase
СК	- Casein kinase
CNS	- Central nervous system
CREB	 cAMP response element binding protein
CRMP	- Collapsin response mediator protein
Cys	- Cysteine
DNA	- Deoxyribonucleic acid
DYRK	- Dual-specificity tyrosine(Y)-phosphorylation-
	regulated kinase
EDTA	- Ethylenediaminetetraacetic acid
EGFR	- Epidermal growth factor receptor
EGTA	- Ethylene glycol tetraacetic acid
ERK	- Extracellular signal regulated kinase
FRAT	- Frequently rearranged in advanced T-cell
GID	Iymphoma - GSK-3 interacting domain
Gin	- Glutamine
Glu	- Glutamic acid
GSK-3	- Glycogen synthase kinase-3
Ile	- Isoleucine
Leu	- Leucine
LC-MS	- Liquid chromatography-mass spectrometry
LRP	- Lipoprotein receptor related protein
LTD	- Long term depression
Lys	- Lysine
МАРК	 Mitogen activated protein kinase
MLCK	- Myosin light chain kinase
MLCK N-terminal	-
-	- Myosin light chain kinase
N-terminal	 Myosin light chain kinase Amino-terminal Nuclear factors of activated T Nylon
N-terminal NFAT	 Myosin light chain kinase Amino-terminal Nuclear factors of activated T Nylon Polymerase chain reaction
N-terminal NFAT NYL	 Myosin light chain kinase Amino-terminal Nuclear factors of activated T Nylon

.....

РКВ -	Protein kinase B
РКС -	Protein kinase C
Pro -	Proline
RNA -	Ribonucleic acid
Ser -	Serine
TCF/LEFs -	T cell factor/lymphoid enhancing factors
ТЕ -	Tris-HCL EDTA
Thr -	Threonine
Tyr -	Tyrosine
Val -	Valine



LIST OF SYMBOLS

Α Alpha -В Beta Ζ Zeta Н Eta Δ Delta Г Gamma Ε Epsilon -% Percentage 32 p Phosphorus-32 (radioactive of isotope _ phosphorus) °C **Degree Celsius** Bp Base pair IC50 Half maximal inhibitory concentration Kb Kilo base *kDA* Kilo Dalton Km Michaelis-Menten constant mМ Mili molar Mm Millimetre MI Millilitre Mg Milligram Mg^{2+} Magnesium ion Molecular weight ALAYSIA SABAH MW [Nano molar nМ Nm Nanometre _ Ng Nano gram _ Micro molar μM -Microgram μg -OD Optical density _ RLU Relative luminescence unit Rotary per minute *Rpm* -S. D. Standard deviation _ ΤМ Trademark w/v Weight over volume -Maximum velocity Vmax v/vVolume over volume V Voltan m/z Mass over charge ratio _

LIST OF APPENDICES

Appendix 1	Preparation of buffer and reagents	Page 141
Appendix 2	Preparation of buffer and reagents	142
Appendix 3	Calculation of flow rate and injection volume for semi preparative HPLC column	143
Appendix 4	1) Summarization of soil microfungi database	144
	 Soil origin, purification media, aerial mycelium and substrate mycelium and inhibition zone for positive inhibitors microfungi strains on GSK-3β 	
Appendix 5	Aerial mycelium and substrate mycelium for microfungi strains coded M4-3, M4-5 and M5-1 meanwhile M2-2, M2-3, M3-4 and M6-3 was not available	145
Appendix 6	Aerial mycelium and substrate mycelium for microfungi strains coded Tam5338, Tam6-2 and Tam6-5 meanwhile Tam6-6 is not available	146
Appendix 7	Aerial mycelium and substrate mycelium for microfungi strains coded Tam7-2, MAN15760 and MAN15558	147
Appendix 8	DNA sequence for MAN15558 strain by ABI System (545 bp)	148
Appendix 9	Peak analysis for MAN15558 sequence by ABI System (545 bp)	149
Appendix 10	List of hits from BLASTn for MAN15558 sequence retrieved from http://blast.ncbi.nlm.nih.gov/Blast.cgi	150
Appendix 11	Dry weigh (mg) and inhibition zones (mm) in the screening assay for MAN15558 cultures for every 24 hours	151
Appendix 12	Cultures of MAN15558 strain containing media and mycelium for every 24 hours and their inhibition zone on the screening plate	152

Appendix 13	Developing of chloroform partition uisng TLC plate in various solvents $\%$ (v/v) and their $R_{\rm f}$ value	153
Appendix 14	Mass spectrum of precursor ion 639.1712 m/z for F27-3 after MS based identification using LC-MS/Qtof	154
Appendix 15	Analysis of 639.1664 m/z ion from F2 using MassBank programme, http://www.massbank.jp/MetaboPrediction.html	155
Appendix 16	Analysis of 639.1664 m/z ion from F2 using MassBank programme, http://www.massbank.jp/MetaboPrediction.html	156
Appendix 17	Compounds that satisfied peak substructure relationship and mass spectrum 639.1664 m/z	157
Appendix 18	Overview- first fractionation approach for crude extracts of MAN15558 strain	158
Appendix 19	Overview- second fractionation approach for crude extracts of MAN15558 strain	159
Appendix 20	Reagents and materials used in Kinase-Glo luminescent assay	160
Appendix 21	Varies concentration of ATP used in Kinase-Glo luminescent assay	161
Appendix 22	Relative luminescence units (RLU) for blank reaction, normal reaction and inhibitor reaction	162

CHAPTER 1

INTRODUCTION

Glycogen synthase kinase-3 (GSK-3) is first identified in rabbit skeletal muscle which had phosphorylation activity against glycogen synthase (Embi *et al.*, 1980) and later implicated in diabetes disease (Frame and Cohen, 2001). Active GSK-3 was found in brain which leads to Alzheimer's disease (Bhat *et al.*, 2004). Other studies reported that GSK-3 is also involved in multiple cellular pathway like Wnt signalling (Woodgett, 2001), cell fates and protein synthesis (Jacobs *et al.*, 2012) due to its numerous substrate (Sutherland, 2011). Therefore, GSK-3 activity is not limited to diabetes and Alzheimer's disease but also responsible for regulating most of the central nervous system disorder (Bhat *et al.*, 2004; Avrahami *et al.*, 2013), inflammation and cancers (Mishra, 2010).

UNIVERSITI MALAYSIA SABAH

Scientific studies of GSK-3 activity in several diseases have leads to the development of inhibitor for GSK-3. At present, many GSK-3 inhibitors have been found and reported worldwide by researchers and scholars ranging from chemical element, natural resources, synthetic molecules and peptides (Finkelman and Martinez, 2011). Unfortunately not all of them act specifically on GSK-3 and pass in the trials using model animal even though their inhibitory activity is good in the cell free assay (Kramer *et al.*, 2012). Therefore, searching for GSK-3 inhibitor is still needed and the biggest challenge is to find the inhibitor with better selectivity, confers favourable outcome plus the inhibition of GSK-3 did not prevents the cell to function in a normal ways (Avrahami *et al.*, 2013).